Clinical Trial Update: Gammagard Liquid and rHuPH20 in PID [Phase 3]

View source ↗

Summary

Phase 3 trial update for Gammagard Liquid with rHuPH20 in primary immunodeficiency diseases has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Gammagard Liquid (intravenous immunoglobulin (IVIG) 10% solution)
• rHuPH20 (recombinant human hyaluronidase PH20)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED | Results posted: 2015-12-03